In 2022, local pharmaceutical companies have new options for going overseas!

【Pharmaceutical Network Industry News】In recent years, affected by a series of factors such as favorable policies, capital, and talent returns, China's pharmaceutical enterprises have been enthusiastic about innovation and have accelerated the pace
of going to sea.

Among them, a large number of new and old enterprises, including Hengrui, Fosun Pharma, Gan&Lee Pharmaceutical, Yasheng Pharmaceutical, Nuohui Health, BeiGene Shenzhou, etc.
, have aimed at overseas markets and actively promoted their overseas layout
.

In the choice of overseas markets, in addition to the European and American markets, in recent years, Chinese pharmaceutical companies have also set their sights on emerging markets, of which this year, many local pharmaceutical companies have locked in Singapore
.

On July 19 this year, WuXi AppTec announced that it expects to invest S$2 billion (approximately RMB9.
73 billion) in R&D and production sites
in Singapore over the next ten years.

The company said that the establishment of the new site will further expand the capabilities and scale of WuXi AppTec's integrated enabling platform, and plans to build advanced laboratories and facilities to provide a full range of R&D and production services
for global partners.

On the same day, WuXi Biologics announced its plans to invest US$1.
4 billion (approximately S$2 billion) in the next decade to build an integrated CRDMO service center in Singapore to expand the capabilities and scale of biopharmaceutical discovery, development and large-scale
stock solution and formulation production.

The site is expected to create 1,500 R&D and production specialist jobs when completed, and will add 120,000 litres of biopharmaceutical capacity
to the company in 2026.

On June 15, some media reported that Kexing Group now plans to invest more than S$2 billion (equivalent to 10 billion yuan) to open a new laboratory in Singapore, and cooperate with other local laboratories to specialize in new pathogens and research solutions and other projects
.

It is unclear
how much it will be invested in Singapore.

On June 6, Fosun Pharma announced that its holding subsidiary, Fosun PharmaPte.
, intends to invest no more than S$218 million (equivalent to RMB1.
054 billion) to acquire a 60% stake
in OncoCare.

According to the announcement, OncoCare is currently the largest private oncology specialist medical centre
in Singapore.

After the completion of this transaction, it will be conducive to expanding the layout of Fosun Pharma's medical and health service business in Southeast Asia, and will help promote the improvement
of the Group's all-round solution capabilities in the field of cancer treatment.

On March 7, domestic genomics company SGD announced the acquisition of Proteona, a
biomedical company based in Singapore, Germany and the United States.

With this acquisition, Proteona's marketing network in Asia, Europe, the United States and Canada will help strengthen SGG's position in overseas markets and will also enable SGL to gain Proteona's technical and biomedical market expertise
in single-cell, multi-omics analysis.

In February, Kingsray Biotech announced the launch of a more than 30,000-square-foot manufacturing facility in Singapore to provide highly automated protein and gene preparation services
.

For the reasons why local pharmaceutical companies have chosen Singapore, the analysis believes that the main reason is that Singapore is rich in science and technology and talent resources, and at the same time, in the Southeast Asian market, Singapore's medical reimbursement system and regulations are relatively more perfect, and it has strong policy support for the health industry, and data show that Singapore attaches great importance to investment in the health field - from 2016 to 2020, Singapore's public research funds in the field of health and biomedicine are as high as nearly 3 billion US dollars
。
In addition to local pharmaceutical companies, some multinational pharmaceutical companies including Sanofi, AbbVie, Novartis, Pfizer, Roche, Abbott, BioNTech, Moderna, etc.
have also invested in Singapore and built bases in Singapore to further deepen the Southeast Asian market
.

Disclaimer: Under no circumstances does the information herein or the opinions expressed in this article constitute investment advice
to any person.